Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (20523)	5/11/1998 9:30:00 PM
From: Andreas Helke	Respond to of 32384

I think Ligands plan to acquire Seragen was the reason why they included the ONTAK rights into their Eli Lilly deal. I was not particularly happy with the idea of acquiring Lillys share of the rights of a somewhat obscure drug. But acquiring Seragen really makes sense in my opinion. On june 2 we will either have a new buying opportunity for Ligand stock or a company that has its first product almost approved, its second NDA hopefully filed and three more NDAs in the nearterm pipeline. Since ONTAK will likely get approved this year Ligand has the chance to make serious money in 1999. I think I know now why we have two sets of remarkably differnet 1999 earnings predictions. All those developments plus the spotlight that EntreMed did put on cancer research might lead to the first really decent selling opportunity for Ligand stock. I would really love to get rid of the 10% of my Ligand shares which I consider to be my trading position. Andreas